DK1537114T3 - Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande - Google Patents

Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande

Info

Publication number
DK1537114T3
DK1537114T3 DK03784194T DK03784194T DK1537114T3 DK 1537114 T3 DK1537114 T3 DK 1537114T3 DK 03784194 T DK03784194 T DK 03784194T DK 03784194 T DK03784194 T DK 03784194T DK 1537114 T3 DK1537114 T3 DK 1537114T3
Authority
DK
Denmark
Prior art keywords
treatment
compounds
formula
aldosterone
agents
Prior art date
Application number
DK03784194T
Other languages
Danish (da)
English (en)
Inventor
Kenna Jeffrey Mc
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1537114T3 publication Critical patent/DK1537114T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03784194T 2002-08-07 2003-08-06 Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande DK1537114T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40169302P 2002-08-07 2002-08-07

Publications (1)

Publication Number Publication Date
DK1537114T3 true DK1537114T3 (da) 2006-11-13

Family

ID=31715720

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03784194T DK1537114T3 (da) 2002-08-07 2003-08-06 Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande

Country Status (14)

Country Link
US (1) US7732603B2 (cg-RX-API-DMAC7.html)
EP (1) EP1537114B8 (cg-RX-API-DMAC7.html)
JP (1) JP4533139B2 (cg-RX-API-DMAC7.html)
CN (1) CN100404535C (cg-RX-API-DMAC7.html)
AT (1) ATE335744T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003253387A1 (cg-RX-API-DMAC7.html)
BR (1) BR0313293A (cg-RX-API-DMAC7.html)
CA (1) CA2494636A1 (cg-RX-API-DMAC7.html)
CY (1) CY1106217T1 (cg-RX-API-DMAC7.html)
DE (1) DE60307483T2 (cg-RX-API-DMAC7.html)
DK (1) DK1537114T3 (cg-RX-API-DMAC7.html)
ES (1) ES2270143T3 (cg-RX-API-DMAC7.html)
PT (1) PT1537114E (cg-RX-API-DMAC7.html)
WO (1) WO2004014914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612088B2 (en) * 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
AR049711A1 (es) * 2004-07-09 2006-08-30 Speedel Experimenta Ag Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200813071A (en) * 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
WO2008027284A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
AU2007337659A1 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
KR20110036069A (ko) * 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-a]피라진 화합물
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
CA2793313C (en) 2010-04-02 2018-01-23 Euroscreen Sa Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
CA2849751C (en) 2011-10-03 2019-06-11 Euroscreen Sa Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
JP6469214B2 (ja) 2014-09-25 2019-02-13 オゲダ エス.エー. N−アシル−(3−置換)−(8−置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンの新規キラル合成
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
CN114702495A (zh) 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CA3095367A1 (en) 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) * 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
KR20230080441A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
IL324432A (en) 2023-05-24 2026-01-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder
CN121045094A (zh) * 2025-04-17 2025-12-02 成都地奥制药集团有限公司 氘代的1,2,4-三嗪化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3582315A (en) * 1968-03-22 1971-06-01 Lilly Co Eli Methods and compositions for inhibiting plant growth
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
JPH07101959A (ja) * 1993-09-30 1995-04-18 Sankyo Co Ltd 1−メチルカルバペネム誘導体
DE4341453A1 (de) * 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
EP1537114B1 (en) 2006-08-09
JP4533139B2 (ja) 2010-09-01
CN1688583A (zh) 2005-10-26
CY1106217T1 (el) 2011-06-08
ES2270143T3 (es) 2007-04-01
EP1537114A1 (en) 2005-06-08
JP2006505520A (ja) 2006-02-16
DE60307483T2 (de) 2007-07-05
ATE335744T1 (de) 2006-09-15
PT1537114E (pt) 2006-12-29
WO2004014914A1 (en) 2004-02-19
HK1080290A1 (en) 2006-04-21
CN100404535C (zh) 2008-07-23
DE60307483D1 (de) 2006-09-21
BR0313293A (pt) 2005-06-14
US7732603B2 (en) 2010-06-08
AU2003253387A1 (en) 2004-02-25
CA2494636A1 (en) 2004-02-19
EP1537114B8 (en) 2007-10-03
US20060166973A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
EP1537114B8 (en) Organic compounds as agents for the treatment of aldosterone mediated conditions
DE60321593D1 (de) Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron
WO2008076336A3 (en) Imidazoles as aldosterone synthase inhibitors
EA201070339A1 (ru) Активаторы растворимой гуанилатциклазы
PH12013502342A1 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
IL231576A0 (en) Adamantyl acetamide derivatives as 11-beta-hydroxysteroid dehydrogenase type 1 enzyme inhibitors
WO2009079412A3 (en) Reverse transcriptase inhibitors
ATE369356T1 (de) Pyridazinon-derivate als cdk2-hemmer
WO2006020767A3 (en) Thiazole based inhibitors of atp-utilizing enzymes
CY1108252T1 (el) Χρηση παραγωγων μεθυλενο αμιδης στις καρδιαγγειακες διαταραχες
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
DE602007008723D1 (de) Selektive rock-proteinkinasehemmer und ihre verwendung
WO2007133905A3 (en) Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
NO20080392L (no) Pyrazolpyridinderivater som inhibitorer av beta-adrenergisk receptorkinase 1
NO20081467L (no) Inhibitorer av sennproteaser
IL178968A0 (en) Novel pyridazinone derivatives as inhibitors of cdk2
NO20060247L (no) Substituerte spirobenzazepiner
ZA200609946B (en) Adamantyl-acetamide derivatives as inhibitor of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2005121102A3 (en) Factor viia inhibitor
WO2005118554A3 (en) Factor viia inhibitor
DK1492797T3 (da) 1-Oxa-3-aza-dibenzoazulener som inhibitorer af tumornekrosefaktorproduktion og mellemprodukter til fremstilling deraf
EP1994029A4 (en) POTASSIUM CHANNEL INHIBITORS
ITVA20040015A1 (it) Inibitore di corrosione concentrato per miscele refrigeranti, metodo di produzione di miscele refrigeranti ed inibizione di miscele refrigeranti esaurite.